| scholarly article | Q13442814 |
| P356 | DOI | 10.1161/01.CIR.88.5.2058 |
| P698 | PubMed publication ID | 8222099 |
| P50 | author | Patrick W Serruys | Q63253317 |
| Felix Zijlstra | Q106776158 | ||
| Harry Suryapranata | Q106777432 | ||
| P2093 | author name string | J W Deckers | |
| G R Heyndrickx | |||
| P Close | |||
| G J Laarman | |||
| A A van den Bos | |||
| H R Buller | |||
| J J Rijnierse | |||
| P433 | issue | 5 Pt 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | stable angina | Q3617336 |
| heparin | Q190016 | ||
| hirudin | Q386715 | ||
| angioplasty | Q539795 | ||
| P304 | page(s) | 2058-2066 | |
| P577 | publication date | 1993-11-01 | |
| P1433 | published in | Circulation | Q578091 |
| P1476 | title | Safety and efficacy of recombinant hirudin (CGP 39 393) versus heparin in patients with stable angina undergoing coronary angioplasty | |
| P478 | volume | 88 |
| Q43675014 | A short synthesis of argatroban. a potent selective thrombin inhibitor |
| Q77853784 | ACC/AHA/ACP-ASIM guidelines for the management of patients with chronic stable angina: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Patients With Chronic Stab |
| Q41609750 | Abrupt vessel closure: changing importance, management, and consequences |
| Q40432300 | Antiplatelet drugs. A comparative review |
| Q73364778 | Antithrombotic Therapy during Percutaneous Coronary Intervention |
| Q40457712 | Antithrombotic and thrombolytic therapy in patients undergoing coronary artery interventions: A review |
| Q73815961 | Antithrombotic treatment (argatroban vs. heparin) in coronary angioplasty in angina pectoris: effects on inflammatory, hemostatic, and endothelium-derived parameters |
| Q52314493 | Argatroban During Percutaneous Transluminal Coronary Angioplasty: Results of a Dose-Verification Study. |
| Q42845164 | Crystallographic determination of the structures of human alpha-thrombin complexed with BMS-186282 and BMS-189090 |
| Q41332329 | Developments in antithrombotic therapy: state of the art anno 1996. |
| Q32141801 | Display of functional thrombin inhibitor hirudin on the surface of phage M13. |
| Q34953097 | Gene therapy to promote thromboresistance: local overexpression of tissue plasminogen activator to prevent arterial thrombosis in an in vivo rabbit model |
| Q77295099 | Hirudin causes more bleeding than heparin in a rabbit ear bleeding model |
| Q47281565 | Hirudin versus heparin and low-molecular-weight heparin: and the winner is... |
| Q33335681 | Hirudin-based anticoagulant strategies for patients with suspected heparin-induced thrombocytopenia undergoing percutaneous coronary interventions and bypass grafting |
| Q73286001 | Hirudin: Its Biology and Clinical Use |
| Q33329712 | Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment. |
| Q71567877 | Importance of delaying balloon angioplasty in patients with unstable angina pectoris |
| Q71736481 | Induction of thrombolysis and prevention of thrombus formation by local drug delivery with a double-occlusion balloon catheter |
| Q71814980 | Influence of piroxicam coadministration on pharmacodynamic parameters and the plasma concentration/effect relationship of recombinant hirudin (CGP 39393) |
| Q64382923 | Local adenoviral-mediated expression of recombinant hirudin reduces neointima formation after arterial injury |
| Q47339841 | Local treatment with an antithrombotic drug reduces thrombus size in coronary and peripheral thrombosed arteries |
| Q71827329 | Local treatment with antithrombotic drugs can prevent thrombus formation: An angioscopic and angiographic study |
| Q41675350 | Low molecular weight heparin versus regular heparin or aspirin in the treatment of unstable angina and silent ischemia |
| Q41119393 | Management of intracoronary thrombosis complicating percutaneous transluminal coronary angioplasty |
| Q77522059 | Medical therapies for the prevention of restenosis after percutaneous coronary interventions |
| Q28242881 | Monitoring of recombinant hirudin: assessment of a plasma-based ecarin clotting time assay |
| Q42393055 | New directions in anticoagulant and antiplatelet treatment |
| Q40463597 | Novel Antithrombotic Drugs in Development |
| Q41641521 | Pharmacologic prevention of acute ischemic complications of coronary angioplasty |
| Q34733975 | Pharmacological properties of hirudin and its derivatives. Potential clinical advantages over heparin |
| Q38410604 | Pharmacology and controlled release of hirudin for cardiovascular disorders |
| Q51576071 | Postangioplasty restenosis: platelet activation and the coagulation-fibrinolysis system as possible factors in the pathogenesis of restenosis. |
| Q45859676 | Retroviral vector-mediated expression of hirudin by human vascular endothelial cells: implications for the design of retroviral vectors expressing biologically active proteins |
| Q40431721 | The Role of Thrombin and Thrombin Inhibitors in Coronary Angioplasty |
| Q52533632 | Therapeutic inhibition of thrombin activities, receptors, and production. |
| Q40486965 | Thrombin and antithrombotic therapy in interventional cardiology |
| Q40433424 | Thrombolytic and antithrombotic treatment in myocardial infarction: main achievements and future perspectives |
| Q73446080 | [Direct thrombin inhibitors: their role in the treatment of arterial and venous thrombosis] |
Search more.